This Little-Known Biotech Stock Just Hit a New 5-Year High

Pulse Biosciences (PLSE) surged to a new five-year high, extending what the report describes as strong technical momentum. The article says shares are up more than 100% over the past 52 weeks and highlights projections that revenue could rise 652.38% this year and 236.71% next. It also notes mixed analyst sentiment, with ratings ranging from “Strong Buy” to “Strong Sell,” citing high valuation and the absence of earnings. The company is valued at $2.27 billion and focuses on health innovation using its patented Nano-pulse Stimulation (NPS) technology. The report attributes progress to the CellFX System and its initial commercial application for benign skin lesions. It further cites a “Buy” technical stance from Barchart and a 5-year high of $33.87 on July 20.